NASDAQ:ARLZ - Aralez Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$0.3730 -0.01 (-2.61 %)
(As of 05/25/2018 04:00 PM ET)
Previous Close$0.3730
Today's Range$0.3660 - $0.3948
52-Week Range$0.36 - $2.98
Volume1.14 million shs
Average Volume3.05 million shs
Market Capitalization$25.54 million
P/E Ratio-0.31
Dividend YieldN/A
Beta1.61

About Aralez Pharmaceuticals (NASDAQ:ARLZ)

Aralez Pharmaceuticals logoAralez Pharmaceuticals Inc. operates as a specialty pharmaceutical company in the United States and Canada. It engages in acquiring, developing, and commercializing products in the areas of cardiovascular, pain management, dermatological allergy, and other indications. It offers Zontivity for the reduction of thrombotic cardiovascular events in patients with heart attack or peripheral arterial disease; Toprol-XL, a cardioselective beta-blocker that is indicated for the treatment of hypertension; Fibricor, a fenofibric acid for the treatment of severe hypertriglyceridemia and patients with primary hypercholesterolemia or mixed dyslipidemia; and Blexten, an antihistamine drug for the symptomatic relief of allergic rhinitis and chronic spontaneous urticarial. The company also markets Cambia, a non-steroidal anti-inflammatory drug (NSAID) for the acute treatment of migraine attacks; Soriatane for the treatment of severe psoriasis and other disorders of keratinization; Proferrin, an iron supplement; Fiorinal and Fiorinal C for the relief of tension type headaches; and Bezalip SR, a pan-peroxisome proliferator-activated receptor activator to treat hyperlipidemia, as well as to increase insulin sensitivity and decrease blood glucose levels for the patients with metabolic syndrome. In addition, it provides out-licensed products, which include VIMOVO for the relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, as well as to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers; and Treximet, a migraine medicine. The company was incorporated in 2015 and is headquartered in Mississauga, Canada.

Receive ARLZ News and Ratings via Email

Sign-up to receive the latest news and ratings for ARLZ and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:ARLZ
CUSIP73941U10
Phone905-876-1118

Debt

Debt-to-Equity Ratio-41.79
Current Ratio0.80
Quick Ratio0.75

Price-To-Earnings

Trailing P/E Ratio-0.31
Forward P/E Ratio-0.57
P/E GrowthN/A

Sales & Book Value

Annual Sales$105.95 million
Price / Sales0.24
Cash FlowN/A
Price / CashN/A
Book Value($0.10) per share
Price / Book-3.73

Profitability

EPS (Most Recent Fiscal Year)($1.20)
Net Income$-125,200,000.00
Net Margins-99.50%
Return on Equity-271.44%
Return on Assets-20.46%

Miscellaneous

Employees164
Outstanding Shares67,190,000

Aralez Pharmaceuticals (NASDAQ:ARLZ) Frequently Asked Questions

What is Aralez Pharmaceuticals' stock symbol?

Aralez Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARLZ."

How were Aralez Pharmaceuticals' earnings last quarter?

Aralez Pharmaceuticals (NASDAQ:ARLZ) announced its quarterly earnings data on Tuesday, May, 8th. The company reported ($0.29) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.25) by $0.04. The business earned $38.08 million during the quarter, compared to the consensus estimate of $31.40 million. Aralez Pharmaceuticals had a negative return on equity of 271.44% and a negative net margin of 99.50%. View Aralez Pharmaceuticals' Earnings History.

When is Aralez Pharmaceuticals' next earnings date?

Aralez Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, August, 8th 2018. View Earnings Estimates for Aralez Pharmaceuticals.

What price target have analysts set for ARLZ?

3 Wall Street analysts have issued 12-month price objectives for Aralez Pharmaceuticals' stock. Their forecasts range from $4.00 to $6.00. On average, they expect Aralez Pharmaceuticals' share price to reach $5.00 in the next year. View Analyst Ratings for Aralez Pharmaceuticals.

Are investors shorting Aralez Pharmaceuticals?

Aralez Pharmaceuticals saw a increase in short interest during the month of April. As of April 13th, there was short interest totalling 3,384,012 shares, an increase of 32.7% from the March 30th total of 2,549,281 shares. Based on an average daily volume of 550,492 shares, the short-interest ratio is presently 6.1 days. Approximately 5.5% of the company's shares are short sold.

Who are some of Aralez Pharmaceuticals' key competitors?

Who are Aralez Pharmaceuticals' key executives?

Aralez Pharmaceuticals' management team includes the folowing people:
  • Mr. Adrian Adams, CEO & Director (Age 67)
  • Mr. Andrew I. Koven, Pres & Chief Bus. Officer (Age 60)
  • Dr. James Patrick Tursi, Chief Medical Officer (Age 53)
  • Mr. Michael Kaseta, CFO & Corp. Controller
  • Mr. John E. Barnhardt CPA, Principal Accounting Officer and VP of Fin. & Admin. (Age 68)

Has Aralez Pharmaceuticals been receiving favorable news coverage?

Media coverage about ARLZ stock has been trending somewhat positive recently, Accern Sentiment reports. The research firm rates the sentiment of press coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Aralez Pharmaceuticals earned a media sentiment score of 0.16 on Accern's scale. They also assigned news headlines about the company an impact score of 45.66 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

Who are Aralez Pharmaceuticals' major shareholders?

Aralez Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Wells Fargo & Company MN (1.52%), GSA Capital Partners LLP (0.39%) and Salzhauer Michael (0.33%). Company insiders that own Aralez Pharmaceuticals stock include Adrian Adams, Andrew I Koven, Arthur S Kirsch, Eric Trachtenberg, James Patrick Tursi, Jason Aryeh, Kenneth B Lee Jr, Mark A Glickman, Robert Paul Harris, Scott J Charles and Seth Rudnick. View Institutional Ownership Trends for Aralez Pharmaceuticals.

Which institutional investors are selling Aralez Pharmaceuticals stock?

ARLZ stock was sold by a variety of institutional investors in the last quarter, including GSA Capital Partners LLP. Company insiders that have sold Aralez Pharmaceuticals company stock in the last year include Andrew I Koven, Eric Trachtenberg, James Patrick Tursi, Mark A Glickman and Scott J Charles. View Insider Buying and Selling for Aralez Pharmaceuticals.

Which institutional investors are buying Aralez Pharmaceuticals stock?

ARLZ stock was purchased by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN and Salzhauer Michael. Company insiders that have bought Aralez Pharmaceuticals stock in the last two years include Adrian Adams, Arthur S Kirsch, James Patrick Tursi, Kenneth B Lee Jr and Seth Rudnick. View Insider Buying and Selling for Aralez Pharmaceuticals.

How do I buy shares of Aralez Pharmaceuticals?

Shares of ARLZ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Aralez Pharmaceuticals' stock price today?

One share of ARLZ stock can currently be purchased for approximately $0.3730.

How big of a company is Aralez Pharmaceuticals?

Aralez Pharmaceuticals has a market capitalization of $25.54 million and generates $105.95 million in revenue each year. The company earns $-125,200,000.00 in net income (profit) each year or ($1.20) on an earnings per share basis. Aralez Pharmaceuticals employs 164 workers across the globe.

How can I contact Aralez Pharmaceuticals?

Aralez Pharmaceuticals' mailing address is 7100 WEST CREDIT AVENUE SUITE 101, MISSISSAUGA A6, L5N 0E4. The company can be reached via phone at 905-876-1118 or via email at [email protected]


MarketBeat Community Rating for Aralez Pharmaceuticals (ARLZ)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  164 (Vote Outperform)
Underperform Votes:  161 (Vote Underperform)
Total Votes:  325
MarketBeat's community ratings are surveys of what our community members think about Aralez Pharmaceuticals and other stocks. Vote "Outperform" if you believe ARLZ will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARLZ will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Aralez Pharmaceuticals (NASDAQ:ARLZ) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
3 Wall Street analysts have issued ratings and price targets for Aralez Pharmaceuticals in the last 12 months. Their average twelve-month price target is $5.00, suggesting that the stock has a possible upside of 1,240.48%. The high price target for ARLZ is $6.00 and the low price target for ARLZ is $4.00. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.672.673.003.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $5.00$5.00$5.00$4.00
Price Target Upside: 1,240.48% upside195.86% upside199.40% upside257.14% upside

Aralez Pharmaceuticals (NASDAQ:ARLZ) Consensus Price Target History

Price Target History for Aralez Pharmaceuticals (NASDAQ:ARLZ)

Aralez Pharmaceuticals (NASDAQ:ARLZ) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/20/2018Chardan CapitalReiterated RatingBuyHighView Rating Details
3/15/2018HC WainwrightSet Price TargetBuy$6.00HighView Rating Details
3/14/2018Bloom BurtonDowngradeBuy ➝ AccumulateMediumView Rating Details
10/10/2016GuggenheimSet Price TargetBuy$12.00N/AView Rating Details
(Data available from 5/26/2016 forward)

Earnings

Aralez Pharmaceuticals (NASDAQ:ARLZ) Earnings History and Estimates Chart

Earnings by Quarter for Aralez Pharmaceuticals (NASDAQ:ARLZ)

Aralez Pharmaceuticals (NASDAQ:ARLZ) Earnings Estimates

2018 EPS Consensus Estimate: ($0.68)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.25)($0.25)($0.25)
Q2 20181($0.24)($0.24)($0.24)
Q3 20181($0.12)($0.12)($0.12)
Q4 20181($0.07)($0.07)($0.07)

Aralez Pharmaceuticals (NASDAQ ARLZ) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/7/2018($0.18)N/AView Earnings Details
5/8/20183/31/2018($0.25)($0.29)$31.40 million$38.08 millionViewListenView Earnings Details
3/13/2018n/a($0.34)($0.37)$25.75 million$28.02 millionViewListenView Earnings Details
11/9/2017Q3($0.39)($0.37)$22.87 million$24.30 millionViewN/AView Earnings Details
8/9/20176/30/2017($0.41)($0.42)$21.37 million$27.62 millionViewListenView Earnings Details
5/9/20173/31/2017($0.40)($0.42)$20.23 million$26.00 millionViewListenView Earnings Details
3/13/201712/31/2016($0.26)($0.37)$21.86 million$20.00 millionViewListenView Earnings Details
11/7/2016Q316($0.32)($0.32)$12.23 million$136.00 millionViewListenView Earnings Details
8/9/2016Q216($0.19)($0.27)$9.70 million$12.60 millionViewListenView Earnings Details
5/10/2016Q116($0.53)($0.73)$9.70 million$8.10 millionViewListenView Earnings Details
3/15/2016Q415($0.28)($0.40)$9.25 million$5.97 millionViewListenView Earnings Details
11/9/2015Q315($0.26)($0.25)$5.20 million$5.80 millionViewListenView Earnings Details
8/10/2015Q215$0.04($0.50)$4.60 million$5.20 millionViewListenView Earnings Details
5/8/2015Q115$0.08$0.01$4.70 million$4.40 millionViewListenView Earnings Details
3/9/2015Q414$0.17$0.21$8.55 million$9.90 millionViewListenView Earnings Details
11/6/2014Q314$0.11$0.20$7.50 million$7.50 millionViewListenView Earnings Details
8/7/2014Q214$0.05$0.09$7.10 million$7.40 millionViewListenView Earnings Details
5/8/2014Q1($0.06)$0.09$5.50 million$7.55 millionViewListenView Earnings Details
3/5/2014Q413($0.05)($0.07)$4.35 million$4.70 millionViewListenView Earnings Details
11/6/2013Q313($0.09)($0.16)$3.25 million$2.60 millionViewListenView Earnings Details
8/6/2013Q2 2013($0.20)($0.13)$1.30 million$1.70 millionViewListenView Earnings Details
5/8/2013Q1 2013($0.19)($0.19)$1.43 million$1.40 millionViewListenView Earnings Details
3/6/2013Q4 2012($0.21)($0.20)$1.46 million$1.40 millionViewListenView Earnings Details
11/8/2012Q312($0.15)($0.19)$2.73 million$0.90 millionViewN/AView Earnings Details
8/1/2012($0.25)($0.17)ViewN/AView Earnings Details
5/1/2012($0.28)($0.28)ViewN/AView Earnings Details
2/28/2012$2.00$2.04ViewN/AView Earnings Details
11/3/2011($0.24)($0.24)ViewN/AView Earnings Details
7/28/2011($0.19)($0.21)ViewN/AView Earnings Details
5/5/2011($0.23)($0.19)ViewN/AView Earnings Details
3/9/2011$0.56$0.61ViewN/AView Earnings Details
10/28/2010Q3 2010($0.28)($0.29)ViewN/AView Earnings Details
8/3/2010Q2 2010$0.54$0.53ViewN/AView Earnings Details
4/29/2010Q1 2010($0.18)($0.10)ViewN/AView Earnings Details
3/3/2010Q4 2009($0.22)($0.19)ViewN/AView Earnings Details
10/28/2009Q3 2009$0.17$0.22ViewN/AView Earnings Details
7/28/2009Q2 2009($0.16)($0.14)ViewN/AView Earnings Details
4/30/2009Q1 2009($0.22)($0.12)ViewN/AView Earnings Details
2/25/2009Q4 2008($0.25)($0.14)ViewN/AView Earnings Details
10/29/2008Q3 2008($0.21)($0.26)ViewN/AView Earnings Details
7/29/2008Q2 2008$0.44$0.43ViewN/AView Earnings Details
5/8/2008Q1 2008($0.24)($0.25)ViewN/AView Earnings Details
2/26/2008Q4 2007($0.18)($0.14)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Aralez Pharmaceuticals (NASDAQ:ARLZ) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
11/21/2013special$1.7512/31/201312/11/201312/30/2013
(Data available from 1/1/2013 forward)

Insider Trades

Aralez Pharmaceuticals (NASDAQ ARLZ) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 6.70%
Institutional Ownership Percentage: 15.79%
Insider Trading History for Aralez Pharmaceuticals (NASDAQ:ARLZ)
Institutional Ownership by Quarter for Aralez Pharmaceuticals (NASDAQ:ARLZ)

Aralez Pharmaceuticals (NASDAQ ARLZ) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/14/2018Andrew I KovenInsiderSell13,964$0.52$7,261.281,339,992View SEC Filing  
3/19/2018Mark A GlickmanInsiderSell5,725$1.70$9,732.50250,188View SEC Filing  
12/8/2017Arthur S KirschDirectorBuy50,000$1.47$73,500.00271,609View SEC Filing  
10/2/2017James Patrick TursiInsiderSell9,960$2.50$24,900.00View SEC Filing  
7/28/2017Scott J CharlesCFOSell10,804$1.25$13,505.00280,551View SEC Filing  
6/23/2017Eric TrachtenbergInsiderSell7,720$1.33$10,267.60201,564View SEC Filing  
6/15/2017Arthur S KirschDirectorBuy15,000$1.15$17,250.00221,609View SEC Filing  
6/14/2017Arthur S KirschDirectorBuy50,000$1.17$58,500.00206,609View SEC Filing  
6/5/2017Andrew I KovenInsiderSell161,906$1.28$207,239.681,363,695View SEC Filing  
5/23/2017Jason AryehDirectorSell388,685$1.44$559,706.4015,000View SEC Filing  
3/20/2017Andrew I KovenInsiderSell7,825$2.41$18,858.251,416,411View SEC Filing  
3/20/2017Scott J CharlesCFOSell5,205$2.41$12,544.05208,163View SEC Filing  
3/15/2017Adrian AdamsCEOBuy500,000$2.46$1,230,000.003,569,230View SEC Filing  
3/15/2017Arthur S KirschDirectorBuy45,000$2.27$102,150.00149,109View SEC Filing  
3/15/2017James Patrick TursiInsiderBuy4,750$2.11$10,022.50184,118View SEC Filing  
11/29/2016Robert Paul HarrisDirectorSell104,778$4.99$522,842.22614,094View SEC Filing  
11/28/2016Robert Paul HarrisDirectorSell20,000$4.65$93,000.00614,094View SEC Filing  
11/14/2016Kenneth B Lee JrDirectorBuy1,000$4.95$4,950.0090,452View SEC Filing  
11/11/2016Seth RudnickDirectorBuy30,000$4.77$143,100.0094,391View SEC Filing  
9/15/2016Robert Paul HarrisDirectorSell150,000$5.82$873,000.00669,094View SEC Filing  
5/20/2016James Patrick TursiInsiderBuy10,000$3.75$37,500.00179,368View SEC Filing  
5/16/2016Eric TrachtenbergInsiderBuy10,000$3.76$37,600.00144,500View SEC Filing  
5/13/2016Kenneth B Lee JrDirectorBuy1,000$3.50$3,500.0083,356View SEC Filing  
5/12/2016Andrew I KovenInsiderBuy71,500$3.49$249,535.001,610,306View SEC Filing  
5/12/2016Arthur S KirschDirectorBuy27,500$3.49$95,975.0096,609View SEC Filing  
5/12/2016Scott J CharlesCFOBuy50,000$3.49$174,500.00213,368View SEC Filing  
12/3/2015John R PlachetkaMajor ShareholderSell23,479$8.14$191,119.06506,799View SEC Filing  
11/13/2015John R PlachetkaMajor ShareholderSell150,000$7.00$1,050,000.0046,782View SEC Filing  
11/12/2015Adrian AdamsCEOBuy1,000,000$6.55$6,550,000.002,944,888View SEC Filing  
9/10/2015John E. BarnhardtVPSell18,322$8.78$160,867.1652,112View SEC Filing  
6/18/2015John G FortInsiderSell78,905$10.93$862,431.65View SEC Filing  
6/3/2015Gilda Marie ThomasInsiderSell23,555$7.53$177,369.15View SEC Filing  
4/15/2015Gilda Marie ThomasInsiderSell25,000$8.61$215,250.00View SEC Filing  
3/17/2015Gilda Marie ThomasInsiderSell50,000$7.51$375,500.00View SEC Filing  
1/2/2015Gilda Marie ThomasVPSell25,000$7.91$197,750.00View SEC Filing  
12/1/2014Par Investment Partners LpMajor ShareholderBuy500,000$7.50$3,750,000.00View SEC Filing  
11/18/2014John R PlachetkaCEOSell50,000$9.00$450,000.00View SEC Filing  
11/6/2014John R PlachetkaCEOSell50,000$9.08$454,000.00View SEC Filing  
10/9/2014John R PlachetkaCEOSell50,000$8.12$406,000.00View SEC Filing  
10/8/2014John R PlachetkaCEOSell32,227$8.16$262,972.32View SEC Filing  
9/30/2014John R PlachetkaCEOSell50,000$7.48$374,000.00View SEC Filing  
9/29/2014John R PlachetkaCEOSell38,298$7.53$288,383.94View SEC Filing  
9/15/2014Dennis L McnamaraEVPSell4,275$7.85$33,558.75View SEC Filing  
9/9/2014John R PlachetkaCEOSell50,000$8.24$412,000.00View SEC Filing  
9/8/2014John R PlachetkaCEOSell30,000$8.30$249,000.00View SEC Filing  
8/25/2014John E BarnhardtVPSell4,293$8.25$35,417.25View SEC Filing  
8/20/2014John R PlachetkaCEOSell50,000$7.78$389,000.00View SEC Filing  
8/8/2014John R PlachetkaCEOSell50,000$7.75$387,500.00View SEC Filing  
7/30/2014John R PlachetkaCEOSell50,000$7.34$367,000.00View SEC Filing  
7/9/2014John R PlachetkaCEOSell50,000$8.88$444,000.00View SEC Filing  
7/8/2014John R PlachetkaCEOSell33,551$8.87$297,597.37View SEC Filing  
7/2/2014William L HodgesCFOSell11,414$9.05$103,296.70View SEC Filing  
6/23/2014John E BarnhardtVPSell27,484$8.80$241,859.20View SEC Filing  
6/23/2014William L HodgesCFOSell5,688$9.05$51,476.40View SEC Filing  
6/20/2014William L HodgesCFOSell50,000$9.05$452,500.00View SEC Filing  
6/19/2014William L HodgesCFOSell9,516$9.05$86,119.80View SEC Filing  
6/17/2014William L HodgesCFOSell112,156$9.03$1,012,768.68View SEC Filing  
6/16/2014Dennis L McnamaraEVPSell15,100$9.06$136,806.00View SEC Filing  
6/11/2014Arthur S KirschDirectorSell9,430$9.30$87,699.00View SEC Filing  
6/5/2014Arthur S KirschDirectorSell2,500$8.67$21,675.00View SEC Filing  
6/2/2014Arthur S KirschDirectorSell2,500$8.73$21,825.00View SEC Filing  
5/27/2014Arthur S KirschDirectorSell10,000$8.38$83,800.00View SEC Filing  
5/22/2014John BarnhardtVPSell77,840$8.31$646,850.4042,321View SEC Filing  
5/16/2014John FortInsiderSell4,000$8.49$33,960.0045,005View SEC Filing  
5/16/2014William HodgesCFOSell71,003$8.16$579,384.4866,461View SEC Filing  
4/24/2014John FortInsiderSell13,725$9.61$131,897.2545,005View SEC Filing  
12/20/2013John FortInsiderSell22,500$9.63$216,675.0035,167View SEC Filing  
7/17/2013Par Investment Partners LpMajor ShareholderBuy90,000$5.25$472,500.00View SEC Filing  
12/27/2012John E BarnhardtVPSell5,219$5.25$27,399.75View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Aralez Pharmaceuticals (NASDAQ ARLZ) News Headlines

Source:
DateHeadline
$32.80 Million in Sales Expected for Aralez Pharmaceuticals (ARLZ) This Quarter$32.80 Million in Sales Expected for Aralez Pharmaceuticals (ARLZ) This Quarter
www.americanbankingnews.com - May 24 at 8:59 AM
 Brokerages Anticipate Aralez Pharmaceuticals (ARLZ) Will Announce Earnings of -$0.23 Per Share Brokerages Anticipate Aralez Pharmaceuticals (ARLZ) Will Announce Earnings of -$0.23 Per Share
www.americanbankingnews.com - May 22 at 1:16 AM
Is There An Opportunity With Aralez Pharmaceuticals Inc’s (TSE:ARZ) 39% Undervaluation?Is There An Opportunity With Aralez Pharmaceuticals Inc’s (TSE:ARZ) 39% Undervaluation?
finance.yahoo.com - May 16 at 8:19 AM
Aralez Pharmaceuticals Expected to Post Q2 2018 Earnings of ($0.24) Per Share (ARLZ)Aralez Pharmaceuticals Expected to Post Q2 2018 Earnings of ($0.24) Per Share (ARLZ)
www.americanbankingnews.com - May 14 at 2:50 AM
Aralez Pharmaceuticals: Change In Strategy May Bring A Silver LiningAralez Pharmaceuticals: Change In Strategy May Bring A Silver Lining
seekingalpha.com - May 11 at 5:58 PM
Edited Transcript of ARLZ earnings conference call or presentation 8-May-18 12:00pm GMTEdited Transcript of ARLZ earnings conference call or presentation 8-May-18 12:00pm GMT
finance.yahoo.com - May 10 at 8:24 AM
Your Daily Pharma Scoop: Akcea-Ionis Ad Comm, Aralez US Shut Down, Lynparza EU ApprovalYour Daily Pharma Scoop: Akcea-Ionis Ad Comm, Aralez US Shut Down, Lynparza EU Approval
seekingalpha.com - May 9 at 5:34 PM
Aralez Pharmaceuticals Inc. 2018 Q1 - Results - Earnings Call SlidesAralez Pharmaceuticals Inc. 2018 Q1 - Results - Earnings Call Slides
seekingalpha.com - May 9 at 5:34 PM
BRIEF-Aralez Pharmaceuticals Reports Q1 Loss Per Share Of $0.29BRIEF-Aralez Pharmaceuticals Reports Q1 Loss Per Share Of $0.29
www.reuters.com - May 9 at 5:34 PM
BRIEF-Aralez Pharmaceuticals Announces Discontinuation Of US Commercial Operations, With Reductions In ...BRIEF-Aralez Pharmaceuticals Announces Discontinuation Of US Commercial Operations, With Reductions In ...
www.reuters.com - May 9 at 5:34 PM
Today’s Research Reports on Stocks to Watch: Amedica Corporation and Aralez PharmaceuticalsToday’s Research Reports on Stocks to Watch: Amedica Corporation and Aralez Pharmaceuticals
finance.yahoo.com - May 9 at 5:34 PM
 Analysts Set $5.83 Price Target for Aralez Pharmaceuticals (ARLZ) Analysts Set $5.83 Price Target for Aralez Pharmaceuticals (ARLZ)
www.americanbankingnews.com - May 9 at 11:57 AM
AKCA Faces FDA Panel Tomorrow, ALDR To Report Data In June, TCMD Riding HighAKCA Faces FDA Panel Tomorrow, ALDR To Report Data In June, TCMD Riding High
www.nasdaq.com - May 9 at 8:18 AM
Aralez Pharma (ARLZ) Announces New Strategic Decisions; Will Focus on Strong Canadian Business, Discontinue Remaining U.S. Commercial BusinessAralez Pharma (ARLZ) Announces New Strategic Decisions; Will Focus on Strong Canadian Business, Discontinue Remaining U.S. Commercial Business
www.streetinsider.com - May 8 at 5:39 PM
Aralez Pharmaceuticals (ARLZ) CEO Adrian Adams on Q1 2018 Results - Earnings Call TranscriptAralez Pharmaceuticals' (ARLZ) CEO Adrian Adams on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 8 at 5:39 PM
Aralez Pharmaceuticals (ARLZ) Issues  Earnings ResultsAralez Pharmaceuticals (ARLZ) Issues Earnings Results
www.americanbankingnews.com - May 8 at 9:52 AM
Aralez Pharmaceuticals misses by $0.04, beats on revenueAralez Pharmaceuticals misses by $0.04, beats on revenue
seekingalpha.com - May 8 at 8:16 AM
Aralez Pharmaceuticals to wind down U.S. operations; shares off 22% premarketAralez Pharmaceuticals to wind down U.S. operations; shares off 22% premarket
seekingalpha.com - May 8 at 8:16 AM
Aralez Announces New Strategic DirectionAralez Announces New Strategic Direction
finance.yahoo.com - May 8 at 8:16 AM
Aralez Pharmaceuticals: 1Q Earnings SnapshotAralez Pharmaceuticals: 1Q Earnings Snapshot
finance.yahoo.com - May 8 at 8:16 AM
Aralez Announces First Quarter 2018 Financial ResultsAralez Announces First Quarter 2018 Financial Results
finance.yahoo.com - May 8 at 8:16 AM
 Brokerages Anticipate Aralez Pharmaceuticals (ARLZ) Will Post Quarterly Sales of $31.40 Million Brokerages Anticipate Aralez Pharmaceuticals (ARLZ) Will Post Quarterly Sales of $31.40 Million
www.americanbankingnews.com - May 6 at 2:40 AM
 Brokerages Expect Aralez Pharmaceuticals (ARLZ) to Announce -$0.25 Earnings Per Share Brokerages Expect Aralez Pharmaceuticals (ARLZ) to Announce -$0.25 Earnings Per Share
www.americanbankingnews.com - May 4 at 5:21 PM
Aralez Pharmaceuticals (ARLZ) Scheduled to Post Quarterly Earnings on TuesdayAralez Pharmaceuticals (ARLZ) Scheduled to Post Quarterly Earnings on Tuesday
www.americanbankingnews.com - May 1 at 7:12 AM
Aralez Pharmaceuticals (ARLZ) Sees Large Growth in Short InterestAralez Pharmaceuticals (ARLZ) Sees Large Growth in Short Interest
www.americanbankingnews.com - April 28 at 2:04 AM
Aralez To Announce First Quarter 2018 Results On May 8, 2018Aralez To Announce First Quarter 2018 Results On May 8, 2018
finance.yahoo.com - April 27 at 8:29 AM
Veeva Commercial & Medical Summit Brings Together Worlds Most Innovative Life Sciences CompaniesVeeva Commercial & Medical Summit Brings Together World's Most Innovative Life Sciences Companies
www.businesswire.com - April 23 at 8:15 AM
Zacks: Analysts Anticipate Aralez Pharmaceuticals (ARLZ) Will Announce Quarterly Sales of $31.40 MillionZacks: Analysts Anticipate Aralez Pharmaceuticals (ARLZ) Will Announce Quarterly Sales of $31.40 Million
www.americanbankingnews.com - April 19 at 2:50 AM
-$0.25 Earnings Per Share Expected for Aralez Pharmaceuticals (ARLZ) This Quarter-$0.25 Earnings Per Share Expected for Aralez Pharmaceuticals (ARLZ) This Quarter
www.americanbankingnews.com - April 17 at 3:19 PM
Head to Head Survey: Synergy Pharmaceuticals (SGYP) versus Aralez Pharmaceuticals (ARLZ)Head to Head Survey: Synergy Pharmaceuticals (SGYP) versus Aralez Pharmaceuticals (ARLZ)
www.americanbankingnews.com - April 14 at 7:43 AM
$31.40 Million in Sales Expected for Aralez Pharmaceuticals (ARLZ) This Quarter$31.40 Million in Sales Expected for Aralez Pharmaceuticals (ARLZ) This Quarter
www.americanbankingnews.com - April 2 at 3:02 AM
Aralez Pharmaceuticals (ARLZ) Short Interest UpdateAralez Pharmaceuticals (ARLZ) Short Interest Update
www.americanbankingnews.com - March 31 at 3:18 AM
Aralez Pharmaceuticals (ARLZ) Given Buy Rating at Chardan CapitalAralez Pharmaceuticals (ARLZ) Given Buy Rating at Chardan Capital
www.americanbankingnews.com - March 22 at 8:12 PM
Aralez Pharmaceuticals Expected to Earn FY2018 Earnings of ($0.70) Per Share (ARLZ)Aralez Pharmaceuticals Expected to Earn FY2018 Earnings of ($0.70) Per Share (ARLZ)
www.americanbankingnews.com - March 21 at 9:32 AM
Aralez Pharmaceuticals Expected to Earn Q1 2018 Earnings of ($0.25) Per Share (ARLZ)Aralez Pharmaceuticals Expected to Earn Q1 2018 Earnings of ($0.25) Per Share (ARLZ)
www.americanbankingnews.com - March 20 at 8:24 AM
Edited Transcript of ARLZ earnings conference call or presentation 13-Mar-18 12:30pm GMTEdited Transcript of ARLZ earnings conference call or presentation 13-Mar-18 12:30pm GMT
finance.yahoo.com - March 18 at 8:16 AM
Bloom Burton Downgrades Aralez Pharmaceuticals (ARLZ) to AccumulateBloom Burton Downgrades Aralez Pharmaceuticals (ARLZ) to Accumulate
www.americanbankingnews.com - March 16 at 9:54 PM
Aralez Pharmaceuticals: Oversold And Undervalued - Aralez ... - Seeking AlphaAralez Pharmaceuticals: Oversold And Undervalued - Aralez ... - Seeking Alpha
seekingalpha.com - March 16 at 8:19 AM
Aralez Pharmaceuticals (ARLZ) Given a $6.00 Price Target by HC Wainwright AnalystsAralez Pharmaceuticals (ARLZ) Given a $6.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - March 15 at 10:30 PM
Aralez Pharmaceuticals (ARLZ) CEO Adrian Adams on Q4 2017 Results - Earnings Call Transcript - Seeking AlphaAralez Pharmaceuticals' (ARLZ) CEO Adrian Adams on Q4 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - March 14 at 8:32 AM
Aralez Pharmaceuticals (ARLZ) Posts  Earnings Results, Misses Expectations By $0.03 EPSAralez Pharmaceuticals (ARLZ) Posts Earnings Results, Misses Expectations By $0.03 EPS
www.americanbankingnews.com - March 13 at 1:18 PM
Form 8-K Aralez Pharmaceuticals For: Mar 13 - StreetInsider.comForm 8-K Aralez Pharmaceuticals For: Mar 13 - StreetInsider.com
www.streetinsider.com - March 13 at 8:25 AM
Aralez Pharmaceuticals Inc. to Host Earnings CallAralez Pharmaceuticals Inc. to Host Earnings Call
finance.yahoo.com - March 13 at 8:25 AM
Aralez Announces Fourth Quarter and Full-Year 2017 Financial ResultsAralez Announces Fourth Quarter and Full-Year 2017 Financial Results
finance.yahoo.com - March 13 at 8:25 AM
Pre-Market Earnings Report for March 13, 2018 : HDS, DKS, GDS, DSW, EPZM, NRE, ATRS, MLNT, ARLZ, GNMX ... - NasdaqPre-Market Earnings Report for March 13, 2018 : HDS, DKS, GDS, DSW, EPZM, NRE, ATRS, MLNT, ARLZ, GNMX ... - Nasdaq
www.nasdaq.com - March 12 at 6:40 PM
Aralez To Announce Fourth Quarter And Full-Year 2017 Results On March 13, 2018 - PR Newswire (press release)Aralez To Announce Fourth Quarter And Full-Year 2017 Results On March 13, 2018 - PR Newswire (press release)
www.prnewswire.com - March 7 at 8:17 AM
Select Sands Appoints Mr. Daniel Gillett and Mr. Steven Goldman to the Board of DirectorsSelect Sands Appoints Mr. Daniel Gillett and Mr. Steven Goldman to the Board of Directors
finance.yahoo.com - March 6 at 8:15 AM
Aralez To Announce Fourth Quarter And Full-Year 2017 Results On March 13, 2018Aralez To Announce Fourth Quarter And Full-Year 2017 Results On March 13, 2018
finance.yahoo.com - March 6 at 8:15 AM
Aralez Pharmaceuticals (ARLZ) to Release Quarterly Earnings on MondayAralez Pharmaceuticals (ARLZ) to Release Quarterly Earnings on Monday
www.americanbankingnews.com - March 5 at 2:16 AM
Zacks: Brokerages Anticipate Aralez Pharmaceuticals Inc (ARLZ) Will Post Quarterly Sales of $25.75 MillionZacks: Brokerages Anticipate Aralez Pharmaceuticals Inc (ARLZ) Will Post Quarterly Sales of $25.75 Million
www.americanbankingnews.com - February 27 at 1:10 PM

SEC Filings

Aralez Pharmaceuticals (NASDAQ:ARLZ) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Aralez Pharmaceuticals (NASDAQ:ARLZ) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Aralez Pharmaceuticals (NASDAQ ARLZ) Stock Chart for Saturday, May, 26, 2018

Loading chart…

This page was last updated on 5/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.